For the Inventor, By the Inventor

Enter assignee name

Bedford, MA, United States of America

Ocular Therapeutix, Inc.

USPTO Granted Patents = 18

EPO Patents = 4

Trademarks = 4

Forward Citations = 20

Loading Chart...

Loading Chart...

22 inventors (with patents filed for the assignee):

Charles D Blizzard (11 out of 20 patents)

Michael Goldstein (11 out of 11 patents)

Peter K Jarrett (11 out of 29 patents)

4. Rami El-Hayek (8 out of 17 patents)

5. Andrew Vanslette (5 out of 5 patents)

6. Arthur Driscoll (5 out of 16 patents)

7. Mark Silverberg (4 out of 8 patents)

8. Joseph Iacona (4 out of 4 patents)

9. Erica Kahn (4 out of 4 patents)

10. Noah Silverberg (4 out of 4 patents)

11. Timothy S Jarrett (3 out of 8 patents)

12. Zachary Lattrell (3 out of 3 patents)

13. Ankita D Desai (2 out of 4 patents)

14. Erik Wong (2 out of 2 patents)

15. Eric Dickinson (1 out of 1 patent)

18 patents: Sort by Forward Citations

1. 12453724 - Ocular implant containing a tyrosine kinase inhibitor (2025-10-28),

2. 12357565 - Ocular implant containing a tyrosine kinase inhibitor (2025-07-15),

3. 12329853 - Compositions and methods for treating ocular diseases (2025-06-17),

4. 12310890 - Punctal plug and bioadhesives (2025-05-27),

5. 12226341 - Implant injector device (2025-02-18),

6. 12161753 - Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent (2024-12-10),

7. 12150896 - Punctal plug and bioadhesives (2024-11-26),

8. 12144889 - Methods of treating allergic conjunctivitis (2024-11-19),

9. 12109302 - Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine (2024-10-08),

10. 12023276 - Intracanalicular depot inserter device (2024-07-02),

11. 11779536 - Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine (2023-10-10),

12. 11622935 - Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles (2023-04-11),

13. 11559429 - Punctal plug and bioadhesives (2023-01-24),

14. 11534396 - Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor (2022-12-27),

15. 11458041 - Punctal plug and bioadhesives (2022-10-04),

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. Their proprietary hydrogel technology platform allows for sustained release of medications to address unmet medical needs in ophthalmology. Ocular Therapeutix is dedicated to improving the lives of patients through groundbreaking solutions for eye care.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#37 in Bedford, MA

#1,058 in Massachusetts

#17,414 in US

#33,186 in the World

Bedford, MA, United States of America

Ocular Therapeutix, Inc.

Forward Citations = 20

22 inventors:

Charles D Blizzard (11 out of 20 patents)

Michael Goldstein (11 out of 11 patents)

Peter K Jarrett (11 out of 29 patents)

4. Rami El-Hayek (8 out of 17 patents)

5. Andrew Vanslette (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…